Evolution of Preclinical Models for Glioblastoma Modelling and Drug Screening

Area of Science:

• Neuro-oncology
• Biomedical Engineering
• Cancer Research

Background:

• Isocitrate dehydrogenase wild-type glioblastoma is a highly aggressive brain tumor with poor patient outcomes.
• Limited success in improving patient outcomes despite multimodal treatment and research efforts.
• Physiologically relevant preclinical models are crucial for optimizing drug screening and developing novel therapies.

Purpose of the Study:

• To explore the evolution of preclinical models for glioblastoma (GBM) research.
• To evaluate the advantages and limitations of traditional versus next-generation GBM models.
• To investigate the potential of integrated models for addressing current challenges in GBM drug screening and personalized medicine.

Main Methods:

• Review of traditional in-vitro and in-vivo glioblastoma models.
• Analysis of organoid technology for 3D GBM modeling.
• Evaluation of glioblastoma-on-a-chip (microfluidic) platforms for mimicking tumor microenvironment.
• Assessment of combined approaches for enhanced drug screening.

Main Results:

• Traditional models have limitations in recapitulating the complex tumor microenvironment.
• Organoids capture cellular heterogeneity and tumor architecture.
• Microfluidic chips mimic vascularization and nutrient exchange, offering dynamic systems.
• Organoid and microfluidic technologies represent significant advances for GBM modeling.

Conclusions:

• Organoid and glioblastoma-on-a-chip technologies offer significant advances in modeling the human tumor microenvironment.
• These next-generation models hold potential for high-throughput drug screening and personalized medicine.
• Integrating complementary aspects of various models can address current challenges in glioblastoma research.